Evidence map›Paper›PMID 38849135›Full record

ArticleAJNR. American journal of neuroradiology2024

Stent Retriever AssIsted Lysis Technique with Tirofiban: A Potential Bailout Alternative to Angioplasty and Stenting.

Marc Rodrigo-Gisbert, Matúš Hoferica, Alvaro García-Tornel, Manuel Requena, Marta Rubiera, Marta De Dios Lascuevas, Marta Olivé-Gadea, Francesco Diana, Federica Rizzo, Marian Muchada and 10 more

Abstract readMulticenter Study
In one paragraph

Article in AJNR. American journal of neuroradiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Marc Rodrigo-GisbertFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-7953-3795
Matúš HofericaDepartment of Diagnostic Neuroradiology (M.H., C.C.), Hôpital Purpan, Centre Hospitalier Universitaire, Toulouse, France.ORCID 0000-0002-5830-0722
Alvaro García-TornelFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0003-3633-3002
Manuel RequenaFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-5671-6484
Marta RubieraFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0001-8100-9477
Marta De Dios LascuevasDepartment de Medicina (M.R.-G, A.G.-T., M. Requena, M. Rubiera, M.D.D.L., M.O.-G., F.D., F.R., M.M., T.C., N.R.-V., D.R.-L., J.J., J.P., D.H., C.A.M., A.T., M.R.), Universitat Autònoma de Barcelona, Barcelona, Spain.
Marta Olivé-GadeaFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0003-4637-1598
Francesco DianaDepartment de Medicina (M.R.-G, A.G.-T., M. Requena, M. Rubiera, M.D.D.L., M.O.-G., F.D., F.R., M.M., T.C., N.R.-V., D.R.-L., J.J., J.P., D.H., C.A.M., A.T., M.R.), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0002-3245-917X
Federica RizzoFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Marian MuchadaFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Tomás CarmonaDepartment de Medicina (M.R.-G, A.G.-T., M. Requena, M. Rubiera, M.D.D.L., M.O.-G., F.D., F.R., M.M., T.C., N.R.-V., D.R.-L., J.J., J.P., D.H., C.A.M., A.T., M.R.), Universitat Autònoma de Barcelona, Barcelona, Spain.
Noelia Rodriguez-VillatoroFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-8833-4720
David Rodríguez-LunaFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0001-8053-4536
Jesus JuegaFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0003-1309-0730
Jorge PagolaFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-0725-1369
David HernándezDepartment de Medicina (M.R.-G, A.G.-T., M. Requena, M. Rubiera, M.D.D.L., M.O.-G., F.D., F.R., M.M., T.C., N.R.-V., D.R.-L., J.J., J.P., D.H., C.A.M., A.T., M.R.), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0001-6715-4547
Carlos A MolinaFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Alejandro TomaselloDepartment de Medicina (M.R.-G, A.G.-T., M. Requena, M. Rubiera, M.D.D.L., M.O.-G., F.D., F.R., M.M., T.C., N.R.-V., D.R.-L., J.J., J.P., D.H., C.A.M., A.T., M.R.), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0002-6736-1535
Christophe CognardDepartment of Diagnostic Neuroradiology (M.H., C.C.), Hôpital Purpan, Centre Hospitalier Universitaire, Toulouse, France.ORCID 0000-0003-4287-2627
Marc RibóFrom the Stroke Unit, Department of Neurology (M.R.-G., A.G.-T., M. Requena, M. Rubiera, M.O.-G., F.R., M.M., N.R.-V., D.R.-L., J.J., J.P., C.A.M., M.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain marcriboj@hotmail.com.ORCID 0000-0001-9242-043X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeAngioplasty and stent placement have been described as a bailout technique in individuals with failed thrombectomy. We aimed to investigate Stent retriever AssIsted Lysis (SAIL) with tirofiban before angioplasty and stent placement. MATERIALS AND

methodsPatients from 2 comprehensive stroke centers were reviewed (2020-2023). We included patients with failed thrombectomy and/or underlying intracranial stenosis who received SAIL with tirofiban before the intended angioplasty and stent placement. SAIL consisted of deploying a stent retriever through the occluding lesion to create a bypass channel and infuse 10 mL of tirofiban for 10 minutes either intra-arterially or IV. The stent retriever was re-sheathed before retrieval. The primary end points were successful reperfusion (expanded TICI 2b-3) and symptomatic intracerebral hemorrhage. Additional end points included 90-day mRS 0-2 and mortality.

resultsAfter a median of 3 (interquartile range, 2-4) passes, 44 patients received the SAIL bridging protocol with tirofiban, and later they were considered potential candidates for angioplasty and stent placement bailout (43.2%, intra-arterial SAIL). Post-SAIL successful reperfusion was obtained in 79.5%. A notable residual stenosis (>50%) after successful SAIL was observed in 45.7%. No significant differences were detected according to post-SAIL: successful reperfusion (intra-arterial SAIL, 80.0% versus IV-SAIL, 78.9%;

conclusionsIn patients with stroke in which angioplasty and stent placement are considered, SAIL with tirofiban, either intra-arterial or IV, seems to safely induce sustained recanalization, offering a potential alternative to definitive angioplasty and stent placement.

Indexed as

AngioplastyStentsTirofibanAgedAged, 80 and overFemaleFibrinolytic AgentsHumansMaleMiddle AgedRetrospective StudiesThrombectomyTreatment OutcomeFibrinolytic AgentsTirofiban

Identifiers

PMID38849135
PMCPMC11543088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.